tranexamic acid has been researched along with Marfan Syndrome in 1 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Marfan Syndrome: An autosomal dominant disorder of CONNECTIVE TISSUE with abnormal features in the heart, the eye, and the skeleton. Cardiovascular manifestations include MITRAL VALVE PROLAPSE, dilation of the AORTA, and aortic dissection. Other features include lens displacement (ectopia lentis), disproportioned long limbs and enlarged DURA MATER (dural ectasia). Marfan syndrome (type 1) is associated with mutations in the gene encoding FIBRILLIN-1 (FBN1), a major element of extracellular microfibrils of connective tissue. Mutations in the gene encoding TYPE II TGF-BETA RECEPTOR (TGFBR2) are associated with Marfan syndrome type 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The utility of tranexamic acid (TXA) in patients with Marfan syndrome (MFS) is uncertain given associated aberrations within the vasculature and clotting cascade." | 8.12 | Tranexamic acid use is associated with reduced intraoperative blood loss during spine surgery for Marfan syndrome. ( Ikwuezunma, IA; Margalit, A; Sponseller, PD, 2022) |
| "The utility of tranexamic acid (TXA) in patients with Marfan syndrome (MFS) is uncertain given associated aberrations within the vasculature and clotting cascade." | 4.12 | Tranexamic acid use is associated with reduced intraoperative blood loss during spine surgery for Marfan syndrome. ( Ikwuezunma, IA; Margalit, A; Sponseller, PD, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ikwuezunma, IA | 1 |
| Margalit, A | 1 |
| Sponseller, PD | 1 |
1 other study available for tranexamic acid and Marfan Syndrome
| Article | Year |
|---|---|
Tranexamic acid use is associated with reduced intraoperative blood loss during spine surgery for Marfan syndrome.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Marfan Syndrome; Scoliosis; Tranexamic Acid | 2022 |